News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Conference News AXIOMATIC-TKR: Milvexian Promising for VTE Prevention L.A. McKeown November 15, 2021
News Conference News AHA 2021 GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients Todd Neale November 14, 2021
News Conference News TCT 2021 LAA Closure Feasible in Patients With Thrombus: Registry Michael O'Riordan October 13, 2021
News Daily News HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients Yael L. Maxwell October 12, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Daily News Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b Shelley Wood June 22, 2021
News Conference News ACC 2021 ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 Todd Neale May 17, 2021
News Daily News VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms Todd Neale May 06, 2021
News Daily News Observational Study Supports Continuing Oral Anticoagulation During PCI Michael O'Riordan April 06, 2021
News Features The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive Todd Neale February 08, 2021
News Daily News Thrombotic Events Frequent Among COVID-19 Patients in ICUs Michael O'Riordan October 27, 2020
News Daily News ‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk Michael O'Riordan September 16, 2020
News Conference News ESC 2020 Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism Caitlin E. Cox September 04, 2020